WO1997048384A2 - Marquage de formes posologiques a desintegration rapide - Google Patents

Marquage de formes posologiques a desintegration rapide Download PDF

Info

Publication number
WO1997048384A2
WO1997048384A2 PCT/EP1997/003066 EP9703066W WO9748384A2 WO 1997048384 A2 WO1997048384 A2 WO 1997048384A2 EP 9703066 W EP9703066 W EP 9703066W WO 9748384 A2 WO9748384 A2 WO 9748384A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
dosage forms
characters
gelatin
marks
Prior art date
Application number
PCT/EP1997/003066
Other languages
English (en)
Other versions
WO1997048384A3 (fr
Inventor
Gary W. Posage
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69728147T priority Critical patent/DE69728147T2/de
Priority to SI9730648T priority patent/SI0910346T1/xx
Priority to CA002257305A priority patent/CA2257305C/fr
Priority to AT97928185T priority patent/ATE261719T1/de
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to BR9709907A priority patent/BR9709907A/pt
Priority to IL12760497A priority patent/IL127604A/xx
Priority to NZ332831A priority patent/NZ332831A/en
Priority to JP10502219A priority patent/JP2000512303A/ja
Priority to EP97928185A priority patent/EP0910346B1/fr
Priority to AU32578/97A priority patent/AU735071B2/en
Priority to DK97928185T priority patent/DK0910346T3/da
Publication of WO1997048384A2 publication Critical patent/WO1997048384A2/fr
Publication of WO1997048384A3 publication Critical patent/WO1997048384A3/fr
Priority to NO19985877A priority patent/NO321512B1/no
Priority to HK99102945A priority patent/HK1018001A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Definitions

  • the present invention relates to a method of marking the surface of solid rapidly disintegrating dosage forms using a non-contact marking technique such as laser imprinting and ink-jet printing.
  • Solid rapidly disintegrating dosage forms loaded with a predetermined quantity of an active ingredient are known from GB-A- 1,548,022 (US-4,305,502). These solid dosage forms comprise a porous network of a matrix material carrying an active ingredient, the matrix material consisting of a water-soluble or a water-dispersable carrier material.
  • the solid dosage forms are prepared by freeze-drying or lyophilization of the solvent from a frozen solution or suspension of the matrix material and the active ingredient.
  • GB-A-2, 1 11 ,423 and US-4,371 ,516 disclose such methods of preparing solid dosage forms which are rapidly disintegrated by water and in which a network of matrix material carries a predetermined amount of an active ingredient, particularly a pharmaceutical substance.
  • Such dosage forms find many applications, particularly where it is desired to administer, dispense or otherwise utilise an active ingredient in predetermined unit quantities.
  • certain active ingredients which are used in solution or suspension form, but which are difficult or hazardous to transport or store in such form may be converted into a solid form which can be added by the user to an aqueous medium to produce the desired solution or dispersion containing a predetermined amount of the active ingredient.
  • the active ingredient may be a reagent which can be added to a known amount of aqueous liquid to produce a standardised liquid composition which then can be used, for example, in chemical analysis.
  • the active ingredient may be a diagnostic compound which has to be added to a biological sample (e.g. blood, urine) and thus allows one to determine the amount of a particular constituent present in the sample.
  • a biological sample e.g. blood, urine
  • the active ingredient is a drug substance for human or veterinary use. Rapidly dissolving solid drug dosage forms are particularly suitable for oral administration. When orally administered they generally disintegrate rapidly in the mouth (e.g. within one or two seconds) and thus the dosage form is a particularly advantageous means for administering drugs to humans and animals.
  • Such dosage forms can be used as alternatives to conventional tablets, pills or capsules, particularly for patients - humans and animals alike - who have difficulty in swallowing these conventional dosage forms.
  • US-4,642,903 teaches a procedure for preparing a freeze-d ⁇ ed foam dosage form using conventional lyophilization techniques which results in rapidly dissolving pharmaceutical dosage forms.
  • WO-93/23017 addresses a problem intrinsic to conventional lyophilization methods namely the lack of uniform porosity in the lyophihzed product. Uniform porosity in a lyophilized product is critical for post-loading a placebo or unloaded dosage form with an active ingredient. WO-93/23017 concerns a method of producing a dosage form that will avoid cracking and meltback, has adequate strength, and porosity and exhibits a fast speed of dissolution.
  • Solid dosage forms as provided by the prior art are used to deliver predetermined amounts of active ingredients. Since the administration of such products is associated with many risks, there is a need to bestow an identity on them. Such risks include, for example, errors in the administration of medicines by physicians, pharmacists or by the end-users, the patients. Several regulatory authorities have issued regulations requiring all solid oral dosage forms to bear a code identifying the product and the holder of the manufacturing authorisation.
  • a mark or text is printed on the dosage form surface, e.g. a company logo or name, a product name, a trade mark, or a number indicating the amount of active ingredient in the dosage form.
  • An alternative solution applicable to tablets consists of intagliatmg the surface thereof by a compression punching, incision or engraving procedure. The intagliations can be highlighted by filling with an optically anisotropic substance (e.g.
  • EP-0,060,023 and EP-0,096,982) by dry filling with a material having a different colour (EP-0,088,556) or by wet filling with a material having a different colour (EP-0,501,553).
  • the present invention provides two such non-contact marking methods, namely laser imprinting and ink-jet printing.
  • a laser is used to etch marks and / or characters into the surface of the dosage form by vaporizing a shallow and narrow portion of the surface.
  • a first mode of etching the marks and / or characters into the surface of the dosage form comprises passing the laser beam through a mask or stencil, preferably in metal, precut with the desired information.
  • the laser beam forms an image of the mask and is then directed onto the surface of the part of the solid dosage form to be marked.
  • the pulsed lasers are used at low pulse energy (a few Joules) and at high repetition rate (e.g. 20 Hz) in order to attain a high, industrially viable mark speed (e.g. 1200 marks/min).
  • An alternative comprises moving a solid dosage form past a plurality of pulsed laser beams arranged along a single line thus creating dot matrix patterns on the surface of the solid dosage form.
  • a third mode of etching the marks and / or characters into the surface of the dosage form comprises scanning a laser beam over the surface of the dosage form using rapidly rotating, computer controlled mirrors.
  • a YAG (yttrium aluminum garnet) or continuous wave carbon dioxide laser is used preferably to etch the product code inforrmation on the surface of a solid dosage form.
  • the vaporized portion of the surface comprises degraded matrix forming materials which are advantageously removed by suction using art-known devices.
  • an ink-jet printer can be used to print marks and / or characters onto the surface of the dosage form by dotting droplets of an ink onto said surface.
  • Prior art methods of ink-jet printing according to the inventor's knowledge, thus far have been applied exclusively to the marking of articles that are substantially impermeable to the ink. Surprisingly, it has proven perfectly possible to extend the ink- jet printing technology to highly porous solid dosage forms.
  • the ink used to mark dosage forms must be suspended or dissolved in a liquid, volatile carrier such as water, alcohol, or mixtures thereof.
  • a liquid, volatile carrier such as water, alcohol, or mixtures thereof.
  • Water based ink jet inks can contain from 70 to 90 % water depending on the nature of the ink. Because of the small droplet size, the solvent evaporates rapidly and does not affect the structure of the solid dosage form.
  • the ink can be edible or non-edible depending on the final use of the dosage form. In case the dosage form comprises a drug for human or veterinary use, obviously only pharmaceutically acceptable, edible inks can be used in the present method of marking the dosage form by means of an ink-jet printer. 97/48384 PC17EP97/03066
  • the above methods are particularly useful when the dosage form is loaded with an active ingredient and is shaped as a tablet.
  • the methods are more particularly suitable when the active ingredient is a drug substance for human or veterinary use and the solid rapidly disintegrating dosage form is a pharmaceutical tablet for oral administration.
  • the dosage form comprises a porous network of matrix forming materials :
  • a water-soluble, hydratable gel or foam-forming material ii) a ⁇ gidifying agent for the gel or foam-forming material, and optionally iii) one or more ammo acids.
  • the solid dosage forms are prepared by lyophilization or by a solid state dissolution technique of a frozen mixture of a solvent with the matrix forming materials. These mixtures may be in a variety of forms such as solutions, suspensions, dispersions, emulsions, foams. Persons skilled in the art will recognize acceptable methods for preparing each of these.
  • Water is preferably employed as the solvent in the composition which is frozen and desolvated.
  • An additional co-solvent such as an alcohol
  • Suitable water-soluble, hydratable gel or foam-forming materials include proteinaceous materials such as gelatin, gelatin A, gelatin B, fluid gelatin, modified fluid gelatin, gelatin derivatives, albumin, soy fiber protein, wheat and psyllium seed proteins, potato protein, papain; phospholipids such as coacervate egg lecithin, or lecithin; gums such as acacia, guar, agar, locust bean, xanthan and tragacanth gum ; polysaccharides such as alginates (polymannuronic acid), chitosan, carrageenans, dextrans, dextrins, maltrins (maltodextrins), pectins (polygalacturonic acid), microcrystallme cellulose, corn syrup solids, konjac flour, rice flour, wheat gluten ; synthetic polymers such as poly vinyl- pyrrolidone, sodium carboxymethylcellulose, sodium starch glycolate, hydroxyethyl-
  • Suitable rigidifying agents include monosaccharides, linear and cyclic oligosaccharides and polysaccharides, e.g. mannitol, xylitol, sorbitol, dextrose, fructose, sucrose, lactose, maltose, galactose, trehalose ; cyclic sugars such as cyclodextrins e.g. beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin ; dextran, dextrin ; and further include inorganic substances such as sodium phosphate, sodium chloride, magnesium aluminum silicates, magnesium trisilicate, natural clays, or a combination thereof.
  • the preferred rigidifying agent is mannitol.
  • Suitable amino acids have from 2 to 12 carbon atoms, e.g. glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine, L-phenylalanine, or a combination thereof.
  • Glycine is the preferred amino acid.
  • Dosage forms containing glycine as one of the matrix forming components have several advantages : quick dissolution and disintegration in aqueous media, pleasant taste and mouthfeel, nutritional value, low caloric content and noncariogenicity. Of particular importance is the fact that these dosage forms can be produced with minimal cracking or meltback and that they have uniform porosity and adequate strength of handling, i.e. resistance to disintegration or crumbling under normal manufacturing and handling conditions. These latter properties contribute to the feasibility of the post-loading processes whereby active ingredients are loaded onto placebo or unloaded dosage forms.
  • Preferred matrix forming agents include pharmaceutical grade gelatins, pectins (nonhydrolyzed, partially hydrolyzed or hydrolyzed), glycine and mannitol.
  • a particularly preferred combination of matrix forming agents comprises gelatin, glycine and mannitol.
  • the solution or dispersion of materials for preparing the matrix can contain from 0.1 % to 15 % by weight of gel or foam forming material, in particular from 1 % to 5 % more in particular from 1.2 % to 3 %. It can further contain from 0.5 % to 10 %, in particular from 0.8 % to 2.5 % by weight of amino acid and from 0.5 % to 10 %, in particular from 1 % to 4 % of rigidifying agent, the remainder being solvent and secondary components as mentioned hereinafter.
  • the ratios between these materials may vary within certain ranges.
  • the weight by weight ratio of the total amount of amino acids to that of the water-soluble, hydratable gel or foam-forming material is from 1 : 1 to 1 : 3.
  • a preferred ratio is
  • the weight by weight ratio of the amount of the water-soluble, hydratable gel or foam-forming material to that of the rigidifying agent is from 2 : 1 to 1 : 2 .
  • a preferred ratio is 1.5 : 2.
  • the weight by weight ratio of the total amount of non-solvent components to that of the water in the aqueous composition is in the range of about 1 : 9 to 1 : 33, in particular from about 1 : 13 to 1 : 30, for example about 1 : 20.
  • Solid rapidly dissolving dosage forms find many applications, particularly where it is desired to administer, dispense or otherwise utilise an active ingredient in predetermined unit quantities.
  • the active ingredient in particular is a drug substance for human of veterinary use.
  • the active ingredient used in the solid rapidly dissolving dosage form may be present in a coated form.
  • it may be present in particulate form and the particles of the active ingredient may be coated with an appropriate coating agent so as to protect it from process diluents, the aqueous environment of the suspension or of the oral or other mucosal cavity, or other environmental conditions that would dissolve or deteriorate said active ingredient.
  • These coating materials may be selected from natural or synthetic polymers that are either hydrophilic or hydrophobic in nature or other hydrophobic materials such a fatty acid, glycerides, triglycerides and mixtures thereof.
  • bitter active ingredients that may be coated in accordance with the present invention include acetaminophen, ibuprofen, chlorpheniramine maleate, pseudo-ephedrine, dextromethorphan, cisapride, domperidone, risperidone.
  • Pharmaceutical applications comprise dosage forms having mucoadhesive properties or designed to deliver a drug at a controlled rate; dosing units designed to deliver drugs in the eye, in vaginal, rectal and other body orifices; solid dosage forms designed to replace liquid formulations; dry medicated preparations for topical application after resolvation (reconstitution); preparation of medicated units or sheets for topical application; preparation of more palatable dosage forms of drugs that exhibit disagreeable organoleptic properties; dosage forms for oral delivery of drugs to persons who have difficulty swallowing tablets or capsules.
  • Secondary components such as nutrients, vitamins, other active ingredients, sweeteners, flavouring agents, colouring agents, surfactants, preservatives, antioxidants, viscosity enhancers, minerals, diagnostics, fertilizers and insecticides may also be incorporated in the formulation of the dosage form.
  • the solution or suspension of which the dosage forms are made may further contain the secondary components mentioned before.
  • Xanthan gum or polyacrylic acid polymers and salts thereof also referred to as carbomers or carboxyvinyl polymers, e.g. CarbopolTM
  • carbomers or carboxyvinyl polymers e.g. CarbopolTM
  • the aqueous compositions may be frozen by any conventional cooling process.
  • the mixture may be frozen by dispensing it into preformed molds corresponding to the size and shape of the desired dosage form and subsequently cooling such molds on refrigerated shelves or in refrigerated chambers.
  • the molds containing the mixture may be passed through a stream of cold gas or vapor, such as liquid nitrogen in a freezing tunnel.
  • the composition is passed through a freezing tunnel into which liquid nitrogen is injected, the liquid nitrogen being vaporised and the resulting cold gaseous nitrogen being passed over the composition.
  • Another method for frreezing the mixtures in the molds is to surround the molds in dry ice until the mixture has frozen.
  • the best-known process of removing solvents from frozen solutions or dispersions is lyophilization which involves desolvation of the mixture by sublimation of the solvent under a vacuum.
  • the frozen compositions may be stored in a cold store before the sublimation process is carried out.
  • the sublimation may be carried out in a freeze drier by subjecting the frozen composition in the mold to reduced pressure and, if desired, controlled application of heat to aid the sublimation.
  • the pressure can be below 4 mmHg (533 Pa), e.g. below 0.3 mmHg (40 Pa), for example 0.1 to 0.2 miriHg ( 13.3 to 26.6 Pa) or even below 0.05 mmHg (6.7 Pa).
  • the initial temperature in the freeze drier may be, for example, as high as 60°C and this temperature can be reduced (e.g. to 40°C) as the temperature of the frozen composition increases.
  • This temperature can be reduced (e.g. to 40°C) as the temperature of the frozen composition increases.
  • the frozen compositions also may be removed from the mold prior to lyophilization.
  • the dosage forms can also be prepared by a solid-state dissolution method of removing solid solvent from solidified samples.
  • one or more delivery matrix forming agents are dissolved or dispersed in a first solvent, frozen and subsequently contacted with a second solvent at a temperature at or higher than the solidification point of the second solvent and at a temperature at or lower than the solidification point of the first solvent.
  • the first solvent in the solidified state is substantially miscible with the second solvent, while the matrix forming agent(s) are substantially insoluble in the second solvent.
  • the first solvent is thereby substantially removed from the solidified matrix yielding a solid matrix substantially free of the first solvent.
  • the first solvent is water and the second ethanol.
  • the mold can be, for example a depression in a metal plate (e.g. an aluminium plate).
  • the plate may contain more than one depression, each depression being of the size and shape corresponding to the desired size of the shaped article.
  • the mold may also be a depression in a sheet of filmic material.
  • the filmic material may contain more than one depression.
  • the filmic material may be similar to that employed in conventional blister packs which are used for packaging pharmaceutical tablets and like medicament forms.
  • the filmic material may be made of thermoplastic material with the depressions formed by thermo-forming.
  • the preferred filmic material is a talc-filled polypropylene film or a polyvinyl chloride film.
  • Laminates of filmic material such as polyvinyl chloride/polyvinylidene chloride, polyvinyl chloride / poly- tetrafluorethylene or polyvinyl chloride / polyvinylidene chloride/polyethylene may also be used.
  • thermoformed cups made in talc-filled polypropylene sheets, optionally siliconized with a layer of silicone/simethicone baked on the surface(s) which come into contact with the aqueous composition.
  • Dosage forms may be prepared in a wide variety of sizes, ranging from about 0.25 ml or g to 30 ml or g and larger. Large dosage forms may be advantageously prepared by the solid state dissolution process without the long drying times required by lyophilization.
  • the frozen and desolvated dosage forms may be of a size corresponding to the desired size of two or more dosage forms.
  • the composition may be frozen in a tray and the solvent removed from the frozen composition to produce a slab or a sheet of desolvated product corresponding in size to that of a number of the desired shaped articles.
  • the sheet may be subdivided to form products of the desired size and the active ingredient may be post-loaded on to the subdivided products by injecting a predetermined amount of a suspension comprising said active ingredient.
  • a particular advantage of this alternative resides in the fact that the subdivision of the sheet does not need to be carried out accurately since a measured amount of active ingredient is added to the subdivided products.
  • the sheet may be dosed with the predetermined amount of active ingredient at selected positions on the sheet prior to subdivision and the sheet subsequently subdivided to give dosage forms each containing the predetermined amount of active ingredient
  • the present invention also provides marked, solid rapidly disintegrating dosage forms obtainable by any one of the processes described hereinbefore
  • the speed with which the maiked tablet prepaied by the inventive method disintegrates is dependent entnely or at least in large part on the choice of matrix forming agent(s), their concentration and the solidif ication/desolvation process conditions
  • dosage forms of the size mentioned in the examples described hereinafter will dissolve or disperse rapidly, for example, in less than about 10 seconds and generally faster e g m less than about 5 seconds or even less, e g within 1 to 2 seconds
  • the dosage forms disperse rapidly in water, e g in less than 10 seconds
  • the disintegration time of a dosage form is determined to check whethei it is capable of being disintegrated by water sufficiently rapidly using a standard tablet disintegration apparatus as described in British Pharmacopoeia, 1980, Vol II, Appendix XII A, but with the standard 2 00 mm wire mesh replaced by stainless steel 40 mesh screen
  • a sample product is placed in a dry tube held above the surface of the water The apparatus is started and the sample immersed in water at 20°C
  • the sample should disperse on the liquid surface and any solid residue should pass through the 40 mesh screen within 10 seconds, preferably within 5 seconds and ideally within 1 to 2 seconds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé pour marquer la surface de formes posologiques solides se désintégrant rapidement. Ce procédé fait appel à une technique de marquage sans contact, comme l'impression par laser ou par jet d'encre.
PCT/EP1997/003066 1996-06-17 1997-06-10 Marquage de formes posologiques a desintegration rapide WO1997048384A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IL12760497A IL127604A (en) 1996-06-17 1997-06-10 Method of making rapidly disintegrating dosage forms
CA002257305A CA2257305C (fr) 1996-06-17 1997-06-10 Marquage de formes posologiques a desintegration rapide
AT97928185T ATE261719T1 (de) 1996-06-17 1997-06-10 Markieren von schnell zerfallenden dosierungsformen
JP10502219A JP2000512303A (ja) 1996-06-17 1997-06-10 迅速に崩壊する投薬形態のマーキング
BR9709907A BR9709907A (pt) 1996-06-17 1997-06-10 Marcacão de formas de dosagem de rápida desintegracão
SI9730648T SI0910346T1 (en) 1996-06-17 1997-06-10 Marking rapidly disintegrating dosage forms
NZ332831A NZ332831A (en) 1996-06-17 1997-06-10 Non-contact marking of pharmaceutical tablets, e.g. laser imprinting or ink-jet printing
DE69728147T DE69728147T2 (de) 1996-06-17 1997-06-10 Markieren von schnell zerfallenden dosierungsformen
EP97928185A EP0910346B1 (fr) 1996-06-17 1997-06-10 Marquage de formes posologiques a desintegration rapide
AU32578/97A AU735071B2 (en) 1996-06-17 1997-06-10 Marking rapidly disintegrating dosage forms
DK97928185T DK0910346T3 (da) 1996-06-17 1997-06-10 Mærkning af hurtigt nedbrydende doseringsformer
NO19985877A NO321512B1 (no) 1996-06-17 1998-12-15 Fremgangsmate for a merke overflaten av faste raskt opplosende doseringsformer og faste raskt opplosende doseringsformer fremstilt ifolge fremgangsmaten
HK99102945A HK1018001A1 (en) 1996-06-17 1999-07-10 Marking rapidly disintegrating dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2027496P 1996-06-17 1996-06-17
US60/020,274 1996-06-17

Publications (2)

Publication Number Publication Date
WO1997048384A2 true WO1997048384A2 (fr) 1997-12-24
WO1997048384A3 WO1997048384A3 (fr) 1998-02-05

Family

ID=21797698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/003066 WO1997048384A2 (fr) 1996-06-17 1997-06-10 Marquage de formes posologiques a desintegration rapide

Country Status (17)

Country Link
EP (1) EP0910346B1 (fr)
JP (1) JP2000512303A (fr)
AT (1) ATE261719T1 (fr)
AU (1) AU735071B2 (fr)
BR (1) BR9709907A (fr)
CA (1) CA2257305C (fr)
DE (1) DE69728147T2 (fr)
DK (1) DK0910346T3 (fr)
ES (1) ES2218686T3 (fr)
HK (1) HK1018001A1 (fr)
IL (1) IL127604A (fr)
NO (1) NO321512B1 (fr)
NZ (1) NZ332831A (fr)
PT (1) PT910346E (fr)
TW (1) TW466179B (fr)
WO (1) WO1997048384A2 (fr)
ZA (1) ZA975279B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044432A1 (fr) * 1999-12-16 2001-06-21 Unilever Plc Comprimes detergents et procede de fabrication
FR2841783A1 (fr) * 2002-07-05 2004-01-09 Duchesnay Inc Forme posologique pharmaceutique portant une signalisation indiquant une parfaite innocuite en cas de grossesse
WO2006051406A2 (fr) * 2004-11-15 2006-05-18 Warner-Lambert Company Llc Bandelette de film medicamentee indicatrice de surdosage
US9988542B2 (en) 2012-07-20 2018-06-05 Otsuka Pharmaceutical Co., Ltd. Tablet having dry-ink film on surface thereof, and ink for inkjet printer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
CN101184478A (zh) * 2005-05-26 2008-05-21 卫材R&D管理有限公司 口服用组合物的标记方法
JP5281009B2 (ja) 2007-08-22 2013-09-04 アステラス製薬株式会社 錠剤印刷装置及び錠剤製造方法並びに錠剤
JP6027800B2 (ja) * 2011-07-15 2016-11-16 沢井製薬株式会社 素錠のマーキング方法
JP5916091B2 (ja) * 2012-01-31 2016-05-11 大原薬品工業株式会社 口腔内崩壊錠のｕｖレーザー印刷方法
CN102975494B (zh) * 2012-11-23 2015-05-20 新昌县捷奥激光制品有限公司 一种胶囊激光打标机
CN103009825B (zh) * 2012-11-23 2015-12-16 新昌县捷奥激光制品有限公司 胶囊检测激光打标一体机

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548825A (en) * 1978-11-15 1985-10-22 Boehringer Ingelheim Gmbh Method for ink-jet printing on uncoated tablets or uncoated tablet cores
CH660750A5 (en) * 1984-11-06 1987-06-15 Thomae Gmbh Dr K Physiologically acceptable inks for printing mouldings having a porous surface by inkjet writing means
WO1993023017A1 (fr) * 1992-05-06 1993-11-25 Janssen Pharmaceutica, Inc. Presentations pharmaceutiques et autres formes galeniques
WO1995009608A1 (fr) * 1993-10-01 1995-04-13 R.P. Scherer Corporation Procede d'application d'une marque sur une forme galenique a dissolution rapide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS615988A (ja) * 1984-06-20 1986-01-11 Toshiba Corp マ−キング方法
JPH04122688A (ja) * 1990-09-13 1992-04-23 Takeda Chem Ind Ltd 錠剤及びカプセルのマーキング方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548825A (en) * 1978-11-15 1985-10-22 Boehringer Ingelheim Gmbh Method for ink-jet printing on uncoated tablets or uncoated tablet cores
CH660750A5 (en) * 1984-11-06 1987-06-15 Thomae Gmbh Dr K Physiologically acceptable inks for printing mouldings having a porous surface by inkjet writing means
WO1993023017A1 (fr) * 1992-05-06 1993-11-25 Janssen Pharmaceutica, Inc. Presentations pharmaceutiques et autres formes galeniques
WO1995009608A1 (fr) * 1993-10-01 1995-04-13 R.P. Scherer Corporation Procede d'application d'une marque sur une forme galenique a dissolution rapide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 010, no. 151 (M-483), 31 May 1986 & JP 61 005988 A (TOSHIBA KK), 11 January 1986, *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 380 (M-1295), 14 August 1992 & JP 04 122688 A (TAKEDA CHEM IND LTD), 23 April 1992, *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044432A1 (fr) * 1999-12-16 2001-06-21 Unilever Plc Comprimes detergents et procede de fabrication
US6677296B2 (en) 1999-12-16 2004-01-13 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Washing tablets marked with indicia on their surfaces
FR2841783A1 (fr) * 2002-07-05 2004-01-09 Duchesnay Inc Forme posologique pharmaceutique portant une signalisation indiquant une parfaite innocuite en cas de grossesse
WO2004004694A1 (fr) * 2002-07-05 2004-01-15 Duchesnay Inc. Forme posologique pharmaceutique avec mise en avant de la compatibilite avec la grossesse
BE1016043A5 (fr) * 2002-07-05 2006-02-07 Duchesnay Inc Forme posologique pharmaceutique portant une signaletique indiquant une parfaite innocuite en cas de grossesse.
US7560122B2 (en) 2002-07-05 2009-07-14 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
WO2006051406A2 (fr) * 2004-11-15 2006-05-18 Warner-Lambert Company Llc Bandelette de film medicamentee indicatrice de surdosage
WO2006051406A3 (fr) * 2004-11-15 2006-08-24 Warner Lambert Co Bandelette de film medicamentee indicatrice de surdosage
US9988542B2 (en) 2012-07-20 2018-06-05 Otsuka Pharmaceutical Co., Ltd. Tablet having dry-ink film on surface thereof, and ink for inkjet printer

Also Published As

Publication number Publication date
DE69728147T2 (de) 2004-10-28
PT910346E (pt) 2004-07-30
DE69728147D1 (de) 2004-04-22
DK0910346T3 (da) 2004-07-12
JP2000512303A (ja) 2000-09-19
ES2218686T3 (es) 2004-11-16
TW466179B (en) 2001-12-01
NO985877L (no) 1999-02-16
EP0910346A2 (fr) 1999-04-28
ZA975279B (en) 1998-12-14
IL127604A0 (en) 1999-10-28
NZ332831A (en) 1999-10-28
AU3257897A (en) 1998-01-07
ATE261719T1 (de) 2004-04-15
NO321512B1 (no) 2006-05-15
WO1997048384A3 (fr) 1998-02-05
EP0910346B1 (fr) 2004-03-17
HK1018001A1 (en) 1999-12-10
IL127604A (en) 2003-05-29
CA2257305A1 (fr) 1997-12-24
CA2257305C (fr) 2006-04-04
BR9709907A (pt) 1999-08-10
AU735071B2 (en) 2001-06-28
NO985877D0 (no) 1998-12-15

Similar Documents

Publication Publication Date Title
CA2257303C (fr) Formes posologiques biconvexes a desintegration rapide
CA2124686C (fr) Preparations lyophilisees et procede pour leur production
CA2135062C (fr) Dosages pharmaceutiques et d'autres types
US5558880A (en) Pharmaceutical and other dosage forms
EP0910346B1 (fr) Marquage de formes posologiques a desintegration rapide
US5529789A (en) Method of producing porous delivery devices
KR100782897B1 (ko) 급속붕괴제형의표시방법
MXPA98010823A (en) Marking of dosed forms of rapida desintegrac
AU677198C (en) Pharmaceutical and other dosage forms
MXPA98010822A (en) Biconvexas forms of dosage that disappear rapidame
KR20000015849A (ko) 양쪽 볼록형 급속붕괴 제형_

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KG KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KG KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997928185

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 332831

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1019980709400

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2257305

Country of ref document: CA

Ref country code: CA

Ref document number: 2257305

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010823

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1997928185

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980709400

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997928185

Country of ref document: EP